1 in 5 people in US with anxiety won’t seek treatment

Research from GeneSight® Mental Health Monitor reveals that 1 in 5 people in the US with anxiety won't seek treatment 

A survey by GeneSight® Mental Health Monitor,  a leader in genetic testing and precision medicine, has found that one in five people with mental health conditions in the US won't seek treatment until these symptoms take a toll on their lives.

Nearly half (46%) of all respondents rated their anxiety symptoms as moderate to severe over the past six months. 

Of those surveyed with a diagnosis of anxiety, 86% rated their symptoms as moderate to severe over the past six months. More than half of those diagnosed say they lived with symptoms for years or decades before seeking treatment. 

Other findings include: 

  • 36% of people who think they have anxiety are planning to seek treatment
  • 47% said a debilitating panic attack would cause them to get treatment
  •  Additional reasons included not being able to leave their homes (34%), sleep issues (31%), an unshakeable feeling of dread (30%) and a negative impact to relationships (30%)

“Imagine waiting until you lose your hearing to treat an ear infection. Patients who are experiencing anxiety symptoms shouldn’t wait to seek treatment,” said Robin Miller, Internist, MD, MHS, owner of Triune Integrative Medicine in Medford, Oregon.

“If you are afraid to go out, experiencing panic attacks, can’t sleep, or your relationships are suffering, you don’t have to live like this. You don't have to wait. You don't have to suffer for years. Help is out there – and treatment can help.” 


Featured Articles

WHO Health Chatbot Built on 'Humanised' GenAI

World Health Organisation's GenAI digital health tool is built using ‘AI humanisation’ tech & designed to ease burden on health workers & educate on health

Costco Weight-Loss Drugs Move Highlights US AOM Growth

Costco move to partner with online healthcare provider Sesame to provide members with weight-loss drugs including Wegovy signals US anti-obesity boom

AstraZeneca Company Profile, as CEO Soriot Lands pay Deal

As it's announced AstraZeneca's CEO Pascal Soriot's package could rise by as much as US$24mn we explore the history of the UK's most valuable business

US Academic Medical Centres 'Struggling' says McKinsey


J&J Community Initiatives Tackle US Healthcare Chasm

Medical Devices & Pharma

PitchBook: Healthcare Private Equity Deals see Decline

Health Insurance & Finance